Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Histologically confirmed adenocarcinoma of the prostate, previously untreated
Potential candidate for radical prostatectomy on the basis of the patient's general medical condition, performance status, and life expectancy
Potential candidate for NHT prior to prostatectomy, including high or intermediate risk of recurrence, based on an estimated risk of biochemical recurrence: High risk category: PSA \>20 or Gleason score 8 or cT2c/cT3 OR Intermediate risk category: PSA \>10 and d20 or Gleason score 7 or cT2b
No evidence of metastatic disease by physical examination, bone scan, and computed tomography, or MRI, of the abdomen and pelvis
Age \> 18 years
ECOG performance status 0-1
Adequate bone marrow, hepatic, and renal function determined within 2 weeks prior to starting therapy
Availability of prostatectomy specimen for histological analysis at the Armed Forces Institute of Pathology
You may not be if
Prior hormone therapy, radiation, chemotherapy, or immunologic therapy for prostate cancer
History of, or significant risk for, chronic inflammatory or autoimmune disease
Potential requirement for systemic corticosteroids before surgery based on prior history
History of autoimmune colitis or chronic GI conditions associated with diarrhea or bleeding, or current acute colitis of any origin
Any serious uncontrolled medical disorder or active infection which would impair ability to receive study treatment and subsequent prostatectomy
Coexisting malignancies except basal or squamous cell carcinoma of the skin
